Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 12/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1772874 | 0.72 | TRPA1 (0.55) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL13996942 | 0.70 | TRPA1 (0.57) | TRPA1MAPTMEN1HTTKMT2A | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL123289 | 0.70 | TRPA1 (1.00) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL16582549 | 0.69 | AHR (0.43) | KDM4E | |
| Dibenzo[B,F][1,4]Oxazepine SCHEMBL30601896 | 0.68 | TRPA1 (0.96) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL12595957 | 0.66 | TRPA1 (0.47) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL12558466 | 0.66 | TRPA1 (0.47) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL16306317 | 0.65 | TRPA1 (0.57) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL1343228 | 0.64 | TRPA1 (0.53) | TRPA1MAPTMEN1HTTKMT2A | |
| SCHEMBL29893783 | 0.64 | TRPA1 (0.50) | TRPA1MAPTMEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | ELDER AMY (US) | 2017-11-30 | — | — | US | disclosed |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION (US) | 2015-10-08 | — | — | US | disclosed |
| US-8912220-B2 | Compounds and methods of use thereof | Galenea Pharmaceuticals | 2014-12-16 | — | — | US | disclosed |
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-8178077-B2 | Drug development target protein and target gene, and method of screening | REVERSE PROTEOMICS RESEARCH INSTITUTE CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | REVERSE PROTEOMICS RESEARCH INSTITUTE CO. (JP) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170342054-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | TRPA1 1440/4885MAPT 1301/4885MEN1 2074/4885 |
| US-20150284365-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | TRPA1 1440/4885MAPT 1301/4885MEN1 2074/4885 |
| US-20090233274-A1 | DRUG DEVELOPMENT TARGET PROTEIN AND TARGET GENE, AND METHOD OF SCREENING | NCS1, PRSS12, TPX2 | TRPA1 4243/4885MAPT 214/4885MEN1 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.